These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18293909)

  • 1. Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor.
    Kane BE; McCurdy CR; Ferguson DM
    J Med Chem; 2008 Mar; 51(6):1824-30. PubMed ID: 18293909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist.
    Kane BE; Nieto MJ; McCurdy CR; Ferguson DM
    FEBS J; 2006 May; 273(9):1966-74. PubMed ID: 16640560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.
    Vortherms TA; Mosier PD; Westkaemper RB; Roth BL
    J Biol Chem; 2007 Feb; 282(5):3146-56. PubMed ID: 17121830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.
    Munro TA; Rizzacasa MA; Roth BL; Toth BA; Yan F
    J Med Chem; 2005 Jan; 48(2):345-8. PubMed ID: 15658846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity.
    Ulens C; Van Boven M; Daenens P; Tytgat J
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1024-33. PubMed ID: 10945855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
    Harding WW; Tidgewell K; Byrd N; Cobb H; Dersch CM; Butelman ER; Rothman RB; Prisinzano TE
    J Med Chem; 2005 Jul; 48(15):4765-71. PubMed ID: 16033256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors.
    Yan F; Mosier PD; Westkaemper RB; Stewart J; Zjawiony JK; Vortherms TA; Sheffler DJ; Roth BL
    Biochemistry; 2005 Jun; 44(24):8643-51. PubMed ID: 15952771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvinorin A: allosteric interactions at the mu-opioid receptor.
    Rothman RB; Murphy DL; Xu H; Godin JA; Dersch CM; Partilla JS; Tidgewell K; Schmidt M; Prisinzano TE
    J Pharmacol Exp Ther; 2007 Feb; 320(2):801-10. PubMed ID: 17060492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.
    Lee DY; Karnati VV; He M; Liu-Chen LY; Kondaveti L; Ma Z; Wang Y; Chen Y; Beguin C; Carlezon WA; Cohen B
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3744-7. PubMed ID: 15993589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.
    Polepally PR; Huben K; Vardy E; Setola V; Mosier PD; Roth BL; Zjawiony JK
    Eur J Med Chem; 2014 Oct; 85():818-29. PubMed ID: 25193297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
    Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.
    Yan F; Roth BL
    Life Sci; 2004 Oct; 75(22):2615-9. PubMed ID: 15369697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric analysis of the opioid receptor domains critical for the binding selectivity of mu opioid ligands.
    Watson B; Meng F; Akil H
    Neurobiol Dis; 1996 Feb; 3(1):87-96. PubMed ID: 9173916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.
    Subramanian G; Paterlini MG; Portoghese PS; Ferguson DM
    J Med Chem; 2000 Feb; 43(3):381-91. PubMed ID: 10669565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
    Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
    J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
    Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
    Lee DY; Deng G; Ma Z; Xu W; Yang L; Liu J; Dai R; Liu-Chen LY
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4689-92. PubMed ID: 26330078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid receptor types and subtypes: the delta receptor as a model.
    Zaki PA; Bilsky EJ; Vanderah TW; Lai J; Evans CJ; Porreca F
    Annu Rev Pharmacol Toxicol; 1996; 36():379-401. PubMed ID: 8725395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
    Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
    J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
    Sheffler DJ; Roth BL
    Trends Pharmacol Sci; 2003 Mar; 24(3):107-9. PubMed ID: 12628350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.